A detailed history of Stifel Financial Corp transactions in Altimmune, Inc. stock. As of the latest transaction made, Stifel Financial Corp holds 60,411 shares of ALT stock, worth $251,913. This represents 0.0% of its overall portfolio holdings.

Number of Shares
60,411
Previous 41,560 45.36%
Holding current value
$251,913
Previous $160,000 41.88%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 12, 2025

BUY
$3.38 - $4.76 $63,716 - $89,730
18,851 Added 45.36%
60,411 $227,000
Q2 2025

Aug 14, 2025

BUY
$3.5 - $7.71 $17,710 - $39,012
5,060 Added 13.86%
41,560 $160,000
Q1 2025

May 13, 2025

BUY
$5.0 - $7.45 $116,985 - $174,307
23,397 Added 178.56%
36,500 $182,000
Q4 2024

Feb 13, 2025

SELL
$6.02 - $9.85 $27,986 - $45,792
-4,649 Reduced 26.19%
13,103 $94,000
Q3 2024

Nov 14, 2024

BUY
$5.5 - $8.1 $42,603 - $62,742
7,746 Added 77.41%
17,752 $108,000
Q2 2024

Aug 13, 2024

BUY
$5.91 - $10.23 $59,135 - $102,361
10,006 New
10,006 $66,000

Others Institutions Holding ALT

About Altimmune, Inc.


  • Ticker ALT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,025,300
  • Market Cap $204M
  • Description
  • Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...
More about ALT
Track This Portfolio

Track Stifel Financial Corp Portfolio

Follow Stifel Financial Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Stifel Financial Corp, based on Form 13F filings with the SEC.

News

Stay updated on Stifel Financial Corp with notifications on news.